Slow-release granisetron (APF530) versus palonosetron for chemotherapy-induced nausea/vomiting: Analysis by American Society of Clinical Oncology emetogenicity criteria

Future Oncology

Volumn 11, Issue 18, 2015, Pages 2541-2551

  Raftopoulos, Harry ^a,b   Boccia, Ralph ^c   Cooper, William ^d   O'Boyle, Erin ^e   Gralla, Richard J ^f  

^a MERCK RESEARCH LABORATORIES   (United States)

^b DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^c Center for Cancer and Blood Disorders   (United States)

^d TFS International   (United States)

^e FIBROGEN INC   (United States)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

APF530; cancer; chemotherapy induced nausea and vomiting; extended release; granisetron; subcutaneous

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; GRANISETRON; METHOTREXATE; PACLITAXEL; PALONOSETRON; PLACEBO; VINBLASTINE; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; DELAYED RELEASE FORMULATION; ISOQUINOLINE DERIVATIVE; QUINUCLIDINE DERIVATIVE; SEROTONIN ANTAGONIST;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DYSPEPSIA; ERYTHEMA; FEMALE; HEADACHE; HIGHLY EMETOGENIC CHEMOTHERAPY; HUMAN; INJECTION SITE CONTUSION; INJECTION SITE REACTION; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MODERATELY EMETOGENIC CHEMOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; ONCOLOGIST; PHASE 3 CLINICAL TRIAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QTC INTERVAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SKIN NODULE; SLOW RELEASE FORMULATION; TREATMENT OUTCOME; AGED; CLINICAL TRIAL; COMPLICATION; DELAYED RELEASE FORMULATION; MIDDLE AGED; NAUSEA; NEOPLASMS; VOMITING;

ADULT; AGED; ANTIEMETICS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DELAYED-ACTION PREPARATIONS; FEMALE; GRANISETRON; HUMANS; ISOQUINOLINES; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; QUINUCLIDINES; SEROTONIN ANTAGONISTS; TREATMENT OUTCOME; VOMITING;

EID: 84942892640     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.15.185     Document Type: Article

References (21)

1. Hesketh PJ, Kris MG, Grunberg SM et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J. Clin. Oncol. 15(1), 103-109 (1997).
2. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N. Engl. J. Med. 358(23), 2482-2494 (2008).
3. NCCN Clinical Practice Guidelines in Oncology: Antiemesis-v1. (2015). www. nccn. org
4. Basch E, Prestrud AA, Hesketh PJ et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline update. J. Clin. Oncol. 29(31), 4189-4198 (2011).
5. Roila F, Herrstedt J, Aapro M et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting: results of the Perugia Consensus Conference. Ann. Oncol. 21(Suppl. 5), v232-v243 (2010).
6. Roila F, Warr D, Aapro M et al. Delayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only). Support. Care Cancer 19(Suppl. 1), S57-S62 (2011).
7. Van Laar ES, Desai JM, Jatoi A. Professional educational needs for chemotherapy-induced nausea and vomiting (CINV): multinational survey results from 2,388 health care providers. Support. Care Cancer 23(1), 151-157 (2015).
8. Kytril (granisetron hydrochloride) injection for intravenous use [prescribing information. Genentech, Inc., South San Francisco, CA, USA (2011). www. Accessdata. fda. gov
9. Heller J, Barr J. Biochronomer technology. Expert Opin. Drug Deliv. 2(1), 169-183 (2005).
10. Raftopoulos H, Cooper W, O'Boyle E, Gabrail N, Boccia R, Gralla RJ. Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority Phase 3 trial. Support. Care Cancer 23, 723-732 (2015).
11. Ottoboni T, Gelder M, O'Boyle E. Biochronomer(tm) technology and the development of APF530, a sustained release formulation of granisetron. J. Exp. Pharmacol. 6, 15-21 (2014).
12. Gabrail N, Yanagihara RH, Spaczynski M et al. Pharmacokinetics, safety, and efficacy of APF530 (extended-release granisetron) in patients receiving moderately or highly emetogenic chemotherapy: results of two Phase II trials. Cancer Manag. Res. 7, 83-92 (2015).
13. Boccia RV, Cooper W, O'Boyle E. Sustained antiemetic responses with APF530 (sustained-release granisetron) during multiple cycles of emetogenic chemotherapy. J. Community Support. Oncol. 13, 38-46 (2015).
14. Aapro MS, Grunberg SM, Manikhas GM et al. A Phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann. Oncol. 17(9), 1441-1449 (2006).
15. Eisenberg P, Figueroa-Vadillo J, Zamora R et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a Phase III, single-dose trial versus dolasetron. Cancer 98(11), 2473-2482 (2003).
16. Gralla R, Lichinitser M, Van Der Vegt S et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized Phase III trial comparing single doses of palonosetron with ondansetron. Ann. Oncol. 14(10), 1570-1577 (2003).
17. Saito M, Aogi K, Sekine I et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: A double-blind, double-dummy, randomised, comparative Phase III trial. Lancet Oncol. 10(2), 115-124 (2009).
18. Hochberg J. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 75(4), 800-802 (1988).
19. Mason JW, Moon TE, O'Boyle E, Dietz A. A randomized, placebo-controlled, four-period crossover, definitive QT study of the effects of APF530 exposure, high dose-intravenous granisetron, and moxifloxacin on QTc prolongation. Cancer Manag. Res. 6, 181-190 (2014).
20. Aloxi (palonosetron HCl) injection for intravenous use (prescribing information). Eisai Inc., Woodcliff Lake, NJ (2014). www. Aloxi. com/docs/pdf/pi. pdf
21. Raftopoulos H, Bria E, Gralla R, Lesser M, Napolitano B, Giannarelli D. Is there a preferred dose of palonosetron-results of an abstract data (AD) meta-analysis (MA) of all eight randomized double-blined (RDB) studies and the impact on guideline considerations. J. Clin. Oncol. 27(15), Abstract 9636 (2009).